
GRTX
Healthcare · Biotechnology · $3.38B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · 30-day revisions 3 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 29, 2026 | Time not confirmed | — | -0.02 | — |
| Mar 26, 2026 | Time not confirmed | — | 2.03 | — |
| Nov 27, 2025 | Time not confirmed | — | -0.01 | — |
| Aug 29, 2025 | Time not confirmed | — | -0.01 | — |
| May 12, 2025 | Before the open | — | -0.09 | — |
| Mar 31, 2025 | Time not confirmed | -0.30 | 0.00 | +100.0% |
| Nov 29, 2024 | Time not confirmed | -0.29 | -0.10 | +64.6% |
| Aug 14, 2024 | Time not confirmed | 0.83 | -0.07 | -108.4% |
| May 13, 2024 | Before the open | -0.29 | -0.08 | +72.7% |
| Mar 28, 2024 | Before the open | -0.35 | -0.10 | +70.7% |
| Nov 14, 2023 | Before the open | -0.40 | -0.33 | +17.5% |
| Aug 14, 2023 | Before the open | -0.38 | -0.48 | -26.3% |
| May 11, 2023 | Before the open | -0.43 | -0.50 | -16.3% |
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory…
| Mar 8, 2023 | Before the open | -0.54 | -0.58 | -7.4% |
| Nov 9, 2022 | Before the open | -0.50 | -0.60 | -20.0% |
| Aug 9, 2022 | Before the open | -0.51 | -0.54 | -5.9% |
| May 16, 2022 | Before the open | -0.57 | -0.58 | -1.8% |
| Mar 10, 2022 | Before the open | -0.76 | -0.64 | +15.8% |
| Nov 10, 2021 | Before the open | -0.77 | -0.86 | -11.7% |
| Aug 10, 2021 | Before the open | -0.83 | -0.88 | -6.0% |
| May 11, 2021 | Before the open | -0.83 | -0.75 | +9.6% |
| Mar 11, 2021 | Before the open | -0.71 | -0.80 | -12.7% |
| Nov 10, 2020 | Before the open | -0.77 | -0.69 | +10.4% |
| Aug 10, 2020 | Before the open | -0.75 | -0.75 | 0.0% |
| May 12, 2020 | Before the open | -0.70 | -0.74 | -5.7% |
| Mar 10, 2020 | Before the open | -0.55 | -1.31 | -138.2% |
| Dec 10, 2019 | Before the open | -0.47 | -0.51 | -8.5% |
| Aug 28, 2019 | Time not confirmed | -0.45 | -0.45 | 0.0% |